middle.news
Alterity’s ATH434 Demonstrates Functional Benefits in MSA with New Composite Scale
10:24am on Wednesday 22nd of April, 2026 AEST
•
Healthcare
Read Story
Alterity’s ATH434 Demonstrates Functional Benefits in MSA with New Composite Scale
10:24am on Wednesday 22nd of April, 2026 AEST
Key Points
ATH434 slowed disease progression on MuSyCA composite scale at 52 weeks
Treatment effect ranged from −1.9 to −4.0 points versus placebo
MuSyCA integrates patient function and neurological exam for sensitivity
Data support regulatory engagement for Phase 3 pivotal trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE